miR-142-5p inhibits proliferation and migration of gastric cancer cells through DNMT1

doi:10.12092/j.issn.1009-2501.2019.12.002

Abstract

Abstract:

AIM: To investigate the role of miR-142-5p in gastric cancer（GC） cells and its mechanism. METHODS: The expression of miR-142-5p was detected by qRT-PCR; the effects of microRNA-142-5p on cell proliferation and migration were studied by CCK8 and Transwell assays; and the target of miR-142-5p was confirmed by dual luciferase reporter assay gene and Western blot assays. RESULTS:The expression of miR-142-5p in GC tissue and cell line was lower than that in normal gastric tissues and GES-1 cells, and the expression level of miR-142-5p was closely related to tumor size and lymph node metastasis. Overexpression of miR-142-5p in MKN28 cells and silencing miR-142-5p in BGC-823 cells inhibited and promoted the proliferation and migration of gastric cancer cells, respectively. DNA methyltransferase 1 (DNMT1) was the direct target of miR-142-5p, which could directly be regulated by miR-142-5p, and miR-142-5p regulated the proliferation and migration of gastric cancer cells through DNMT1. CONCLUSION: miR-142-5p is decreased in GC, implying an anti-oncogenetic effect to inhibit the proliferation and migration of gastric cancer cells by inhibiting DNMT1.

Key words: gastric cancer, miR-142-5p, proliferation, migration, DNA methyltransferase 1

CLC Number:

LI Yuqin, WANG Kai, AO Li, LU Xiaolan, SHI Jianping. miR-142-5p inhibits proliferation and migration of gastric cancer cells through DNMT1[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1328-1334.

References

［1］Pietrantonio F, Miceli R, Raimondi Al et al. Individual patient data Meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer［J］. J Clin Oncol, 2019, JCO1901124.
［2］Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014［J］. CA Cancer J Clin, 2014, 64: 9-29.
［3］Yan C, Zhu M, Ding Y et al. Meta-analysis of genome-wide association studies and functional assays decipher susceptibility genes for gastric cancer in Chinese populations ［J］. Gut, 2019, pii: gutjnl-2019-318760.
［4］Bickenbach K, Strong VE. Comparisons of gastric cancer treatments: east vs. west［J］. J Gastric Cancer, 2012, 12(2): 55-62.
［5］Dong D, Tang L, Li ZY, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer［J］. Ann Oncol, 2019, 30: 431-438.
［6］Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression ［J］. Cell Mol Life Sci, 2019, 76: 441-451.
［7］Zhao XD, Lu YY, Guo H, et al. MicroRNA-7/NF-κB signaling regulatory feedback circuit regulates gastric carcinogenesis［J］. J Cell Biol, 2015, 210: 613-627.
［8］Du W, Tang H, Lei Z, et al. miR-335-5p inhibits TGF-β1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1［J］. Respir Res, 2019, 20: 225.
［9］Hu X, Wang R, Ren Z, et al. MiR-26b suppresses hepatocellular carcinoma development by negatively regulating ZNRD1 and Wnt/β-catenin signaling［J］. Cancer Med, 2019, 8(17): 7359-7371.
［10］Han L, Cui D, Li B, et al. miR-338-5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells via targeting Id-1［J］. Cancer Sci, 2019.
［11］Croce CM. Causes and consequences of microRNA dysregulation in cancer［J］. Nat Rev Genet, 2009, 10: 704-714.
［12］Han TS, Hur K, Xu G, et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1 ［J］. Gut, 2015, 64: 203-214.
［13］Zhang X, Yan Z, Zhang J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection ［J］. Annal Oncol, 2011, 22(10): 2257-2266.
［14］Betel D, Wilson M, Gabow A, et al. The microRNA.org resource: targets and expression［J］. Nucleic Acids Res, 2008, 36: D149-D153.
［15］Zhao R, Zhao L, Xu X, et al. Analysis of microRNA expression profiles reveals a 5-microRNA prognostic signature for predicting overall survival time in patients with gastric adenocarcinoma ［J］. Oncol Rep, 2019, 41: 2775-2789.
［16］Wang Z, Liu Z, Fang X, et al. MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell lung cancer［J］. Cell Physiol Biochem, 2017: 2505-2515.
［17］Cheng D, Li J, Zhang L, et al. miR-142-5p suppresses proliferation and promotes apoptosis of human osteosarcoma cell line, HOS, by targeting PLA2G16 through the ERK1/2 signaling pathway［J］. Oncol Lett, 2019, 17(1): 1363-1371.
［18］Islam F, Gopalan V, Vider J, et al. MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights［J］. Exp Mol Pathol, 2018, 104: 98-107.
［19］Liu S, Xiao Z, Ai F, et al. miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis［J］. Biomed Pharmacothera, 2017, 92: 1119-1127.
［20］Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma［J］. Cancer Res, 2009, 69: 2766-2774.
［21］Zhang BG, Hu L, Zang MD, et al. Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NFκB pathway in gastric cancer development［J］. Oncotarget, 2016, 7: 9788-9800.
［22］Mutze K, Langer R, Schumacher F, et al. DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer［J］. Eur J Cancer, 2011, 47: 1817-1825.
［23］Qiu H, Yashiro M, Shinto O, et al. DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells［J］. Cancer Sci, 2009, 100: 181-188.

[1]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[2]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[3]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[4]	DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua. Study on the treatment of thin endometrium with growth hormone and vitamin E [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
[5]	SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui. Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.
[6]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[7]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[8]	LEI Jing, HE Ping, CAI Wenlin, ZHANG Yongzhe, ZHANG Beiru, LIU Dajun. Cordyceps sinensis extracts attenuates HBx-induced mesangial cell proliferation and extracellular matrix synthesis by suppression of the PI3K/Akt pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1247-1254.
[9]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[10]	JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi. AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
[11]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[12]	CHEN Linjun, CHEN Wenbin. Jolkinolide B inhibits the proliferation and metastasis of colon cancer cells via blocking PI3K/Akt/NF-κB pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 250-257.
[13]	PENG Fusheng, HUANG Xiaohui, LI Peng, TANG Jian'er. miR-34a inhibits proliferation of prostate cancer LNCaP cells by regulating androgen receptor gene [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 10-17.
[14]	WU Yi, ZHU Akao, SHAN Yuqiang, YING Rongchao, JIN Huicheng. Resveratrol regulates miR-409-3p/FKBP14 to inhibit the malignant biological processes of gastric cancer BGC823 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 968-975.
[15]	WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong. Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.